CNTA
Centessa Pharmaceuticals plcHealthcare·Biotechnology
$39.76
$6.2B market cap
Revenue
$0.0M
Free Cash Flow
$-128.0M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has em
2-Year Price History
$39.75+360.6%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -79.8 | -79.8 | -79.2 | -72.2 | -72.2 | -0.0 | 276.6 | 7.4 | 153.6 | -233.9% | -29.3x | -- |
| Act | 2025-Q4 | 0.0 | -88.0 | -68.5 | -66.2 | -55.8 | -55.8 | -0.0 | 294.6 | 7.6 | 135.7 | -152.0% | -31.3x | -- |
Valuation & Metrics
Market Stats
Price$39.76
Market Cap$6.2B
Enterprise Value$5.9B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-2.1%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-145.4M
Free Cash Flow$-128.0M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-193.0%
WC Change % Rev0.0%
Interest Coverage-30.3x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.8M
Days to Cover1.2
Change (vs Prior)-19.3%
Need at least 2 settlement dates for chart
Employees
Headcount77
Revenue / Employee$0
Gross Profit / Employee$-3,099
Cash Runway
25.9months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
95.2%(+66.4% YoY)
153 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
0.5%(+0.4% YoY)
2 filers
Vanguard, iShares, SPDR
Market makers
0.1%(-0.2% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | $793M | $4.87 | +$0 | +$0 | -1.8% | $982M |
| Avoro Capital Advisors LLC | $454M | $21.21 | −$124M | +$293M | +1.1% | $10.15B |
| Index Venture Life Associates VI Ltd | $396M | $4.87 | +$0 | +$0 | -27.6% | $396M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $355M | $14.66 | −$93.6M | +$78.3M | -0.1% | $64.61B |
| Pentwater Capital Management LP | $325M | $39.72 | +$325M | +$325M | -0.7% | $14.07B |
| FMR LLC | $272M | $17.60 | −$83.8M | +$120M | -0.0% | $1.89T |
| EcoR1 Capital, LLC | $238M | $18.31 | +$115M | +$238M | -5.2% | $2.34B |
| PERCEPTIVE ADVISORS LLC | $209M | $20.82 | +$93.0M | +$88.1M | -1.5% | $5.05B |
| Capital World Investors | $192M | $35.13 | +$146M | +$192M | +0.3% | $732.46B |
| FARALLON CAPITAL MANAGEMENT LLC | $191M | $15.09 | −$22.6M | +$18.9M | -0.5% | $15.27B |
| TCG Crossover Management, LLC | $170M | $12.97 | +$0 | +$55.4M | +4.4% | $3.50B |
| MORGAN STANLEY | $170M | $24.16 | +$125M | +$52.9M | -0.3% | $1.65T |
| Paradigm Biocapital Advisors LP | $142M | $39.72 | +$142M | +$142M | +1.9% | $4.69B |
| JANUS HENDERSON GROUP PLC | $139M | $15.87 | −$23.9M | −$96.5M | +1.2% | $209.29B |
| Deep Track Capital, LP | $125M | $27.36 | +$46.0M | +$125M | -1.2% | $4.85B |
| Logos Global Management LP | $84.4M | $38.78 | +$76.5M | +$84.4M | -1.6% | $1.94B |
| RTW INVESTMENTS, LP | $81.6M | $19.25 | +$10.5M | +$79.6M | -2.2% | $9.26B |
| FEDERATED HERMES, INC. | $81.4M | $24.44 | −$11.6M | +$81.4M | -1.1% | $61.33B |
| BRAIDWELL LP | $78.9M | $25.01 | −$8.0M | +$78.9M | -1.8% | $2.63B |
| BANK OF AMERICA CORP /DE/ | $76.8M | $28.83 | +$39.0M | +$68.5M | -0.1% | $1.36T |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
+1.60%
avg per quarter
Holders (ex-self)
-2.19%
excl. this stock
Buyers (this Q)
-0.23%
96 buyers · $1.85B in
Sellers (this Q)
+0.29%
47 sellers · $-0.10B out
alpha coverage: 100% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-4.8%
how holders react when this stock falls
On quiet Qs
-0.4%
−10% to +10% baseline
On rallies (+10%+)
-1.6%
how they react when this stock rises
Holders' portfolio flow this Q
-3.1%
outflows — trims may be forced
Sellers' portfolio flow this Q
+13.1%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-2.7%
Holder mid (any stock)
-1.8%
Holder rally (any stock)
-5.0%
Biggest decreases this quarter
GENERAL ATLANTIC, L.P.−$189Mα-5.1Avoro Capital Advisors LLC−$124Mα+1.1PRICE T ROWE ASSOCIATES INC /MD/exited−$98.2MADAGE CAPITAL PARTNERS GP, L.L.C.−$93.6Mα-0.1FMR LLC−$83.8Mα-0.0STEMPOINT CAPITAL LPexited−$28.9MFirst Light Asset Management, LLC−$28.5Mα-10.7Sofinnova Investments, Inc.exited−$27.6MCommodore Capital LPexited−$25.0MJANUS HENDERSON GROUP PLC−$23.9Mα+1.2
New buyers this quarter
Top-5 holders · 39.4%
Medicxi Ventures Management (Jersey) Ltd--
Avoro Capital Advisors LLC--
Index Venture Life Associates VI Ltd--
ADAGE CAPITAL PARTNERS GP, L.L.C.--
Pentwater Capital Management LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Medicxi Ventures Management (Jersey) Ltd20.0MAvoro Capital Advisors LLC11.4MIndex Venture Life Associates VI Ltd10.0MADAGE CAPITAL PARTNERS GP, L.L.C.8.9MPentwater Capital Management LP8.2MFMR LLC6.9MEcoR1 Capital, LLC6.0MGENERAL ATLANTIC, L.P.1.4MPERCEPTIVE ADVISORS LLC5.3MCapital World Investors4.8M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| ERAS | Erasca, Inc. | 8 | 113.28× |
| NUVL | Nuvalent, Inc. | 6 | 101.95× |
| OLMA | Olema Pharmaceuticals, Inc. | 4 | 101.95× |
| DNTH | Dianthus Therapeutics, Inc. | 10 | 98.03× |
| GLUE | Monte Rosa Therapeutics, Inc. | 3 | 84.96× |
| ALKS | Alkermes plc | 5 | 79.65× |
| SVRA | Savara Inc. | 3 | 76.46× |
| ANAB | AnaptysBio, Inc. | 3 | 76.46× |
| SYRE | Spyre Therapeutics, Inc. | 5 | 74.97× |
| CGON | CG Oncology, Inc. Common stock | 5 | 74.97× |
| MDGL | Madrigal Pharmaceuticals, Inc. | 4 | 72.82× |
| OCUL | Ocular Therapeutix, Inc. | 4 | 72.82× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (2 analysts)$41.00310.0%
Last Year (9 analysts)$36.56-800.0%
Current Price$39.76
Analyst Ratings
8
6
Buy: 8Hold: 6Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$19.26M
33 txns · 6 insiders · 826,357 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-03-26 | SELL | Anderson Karen M. | officer: Chief People Officer | 41,076 | $30.12 | $1.24M | $1.87M |
| 2026-03-26 | SELL | Weinhoff Gregory M | officer: Chief Business Officer | 23,998 | $30.00 | $720K | $1.98M |
| 2026-03-17 | SELL | Anderson Karen M. | officer: Chief People Officer | 10,043 | $28.10 | $282K | $1.74M |
| 2026-03-16 | SELL | Anderson Karen M. | officer: Chief People Officer | 64,768 | $28.21 | $1.83M | $1.75M |
| 2026-03-13 | SELL | Anderson Karen M. | officer: Chief People Officer | 120,029 | $26.25 | $3.15M | $1.63M |
| 2026-03-13 | SELL | Weinhoff Gregory M | officer: Chief Business Officer | 73,196 | $26.33 | $1.93M | $1.74M |
| 2026-02-02 | SELL | HUSSAIN IQBAL J | officer: Chief Legal Officer | 38,951 | $25.15 | $980K | $1.45M |
| 2026-01-30 | SELL | HUSSAIN IQBAL J | officer: Chief Legal Officer | 1,010 | $25.01 | $25K | $2.61M |
| 2025-12-09 | SELL | Accardi Mario Alberto | officer: President, Orexin Program | 10,000 | $28.83 | $288K | $5.15M |
| 2025-12-08 | SELL | Accardi Mario Alberto | officer: President, Orexin Program | 10,000 | $30.00 | $300K | $5.66M |
| 2025-11-17 | SELL | Bush Tia L | officer: Chief Technology & Quality Ofc | 40,000 | $28.00 | $1.12M | $3.40M |
| 2025-11-17 | SELL | HUSSAIN IQBAL J | officer: General Counsel | 6,000 | $27.64 | $166K | $2.91M |
| 2025-11-12 | SELL | Bush Tia L | officer: Chief Technology & Quality Ofc | 40,000 | $26.00 | $1.04M | $3.16M |
| 2025-10-27 | SELL | Accardi Mario Alberto | officer: President, Orexin Program | 8,000 | $25.00 | $200K | $4.86M |
| 2025-10-15 | SELL | HUSSAIN IQBAL J | officer: General Counsel | 6,000 | $22.41 | $134K | $2.36M |
| 2025-09-24 | SELL | Bush Tia L | officer: Chief Technology & Quality Ofc | 35,000 | $24.00 | $840K | $2.92M |
| 2025-09-16 | SELL | Accardi Mario Alberto | officer: President, Orexin Program | 8,172 | $21.40 | $175K | $4.22M |
| 2025-09-15 | SELL | HUSSAIN IQBAL J | officer: General Counsel | 6,000 | $21.85 | $131K | $2.30M |
| 2025-09-10 | SELL | Bush Tia L | officer: Chief Technology & Quality Ofc | 25,000 | $22.00 | $550K | $2.67M |
| 2025-09-10 | SELL | HUSSAIN IQBAL J | officer: General Counsel | 20,000 | $22.00 | $440K | $2.32M |
Order Flow (FINRA, ~3w lag)
54.0%retail+11.6pp
19.9%dark-9.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
CENTESSA PHARMACEUTICALS PLC: High-Burn Biotech Engine Fueled by Aggressive Equity Dilution and Restructuring Reversals
Overall Risk
6/10
Fraud
2/10
Dilution
8/10
Insolvency
5/10
Earnings Overstated
4/10
Hidden Liabilities
3/10
Legal
2/10
Audit Warnings
3/10
Hidden Upside
6/10
Contextually Acceptable
7/10